KaloBios Pharma (KBIO) Announces Filing of 10-Q, 10-K for 2015
- Healthcare, tech stocks drive Wall Street higher
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Qualcomm (QCOM) to Acquire NXP Semi (NXPI) in $47B Deal
- Tesla (TSLA) Posts Q3 adj.-EPS of 71c
- Pre-Open Stock Movers 10/27: (PRQR) (OCN) (TWTR) Higher; (CYH) (GNC) (RNWK) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
KaloBios Pharmaceuticals, Inc. (OTC: KBIO) announced the filing with the U.S. Securities and Exchange Commission (SEC) of the company’s Form 10-Q for the three and nine months ended September 30, 2015, and its Form 10-K for the fiscal year ended December 31, 2015.
The filings mark an important step towards the achievement of one of the company’s key near-term goals of regaining compliance with periodic reporting requirements of the SEC and to seek relisting on a national securities exchange.
“Our momentum continues to build due to our intense focus on executing our strategic priorities,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We intend to be back in compliance with our filings as expeditiously as possible, as we also work to strengthen our financial position and accelerate our pipeline programs.”
KaloBios emerged from bankruptcy on June 30, 2016, with new management and a transformational strategy, including the Responsible Pricing Model.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AK Steel (AKS) Prices 65M Share Common Stock Offering for Proceeds of ~$318.5M
- Ritter Pharmaceuticals (RTTR) Prices 2.13M Share Common Offering for Proceeds of $5M
- Telesat Reports Preliminary Revenue Q3 of $235M
Create E-mail Alert Related CategoriesCorporate News, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!